Harmony Biosciences posts results of Phase 3 pitolisant study in idiopathic hypersomnia
Results for the open-label study were first posted on ClinicalTrials.gov on November 13, 2026. The completed study enrolled 119 participants and assessed the long-term safety and effectiveness of pitolisant after the double-blind randomized withdrawal phase of HBS-101-CL-010.
Primary source
ClinicalTrials.gov results record, November 13, 2026
A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia
Read the source: A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation